Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
Jemilat Salami(Yale University), Craig M. Crews(Yale University)
Cited by 343
Related Papers
PROTAC targeted protein degraders: the past is prologue
|Nature Reviews Drug Discovery|2022|2.9k
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
|Nature Communications|2019|516
Targeted Protein Degradation by Small Molecules
|The Annual Review of Pharmacology and Toxicology|2016|203
Mutant-selective degradation by BRAF-targeting PROTACs
|Nature Communications|2021|135
Modulation of Phosphoprotein Activity by Phosphorylation Targeting Chimeras (PhosTACs)
|ACS Chemical Biology|2021|122